The capital markets are experiencing a renaissance of sorts, with a robust IPO pipeline that reflects both technological innovation and shifting investor priorities. Companies across diverse sectors are positioning themselves for public debuts, creating one of the most anticipated periods for initial public offerings in recent memory. This surge represents more than just market timing—it […]
There is no excerpt because this is a protected post.
When Tesla reported a stunning 17% revenue beat in October 2024, sending shares soaring 22% in after-hours trading, it reminded investors of a fundamental truth: earnings surprise events can create or destroy wealth in mere hours. As Q4 earnings season unfolds, understanding how to identify, analyze, and capitalize on these surprise moments has become essential […]
There is no excerpt because this is a protected post.
Helus Pharma (NASDAQ: HELP) is a clinical-stage biotech with FDA Breakthrough Therapy Designation for its lead depression therapy HLP003, now in Phase 3 trials. With $195 million in cash, a Jefferies BUY rating at $22, and a new CEO who helped build Vyvanse into a multi-billion dollar franchise, 2026 catalysts are stacking up.
Golden Goose Resources (CSE: GGR) is proving that strategic addresses define project value in the 2026 cycle. The company’s flagship La Esperanza project in Argentina has delivered 24 g/t gold intercepts directly adjacent to Southern Copper’s active drill sites. In Quebec, the Goldfire property covers 83 claims sitting next to the 4.1-million-ounce Windfall deposit owned by Gold Fields. This elite positioning highlights the discovery potential of Golden Goose Resources (CSE: GGR).
China banned silver exports, and the U.S. responded by designating silver a national security priority. As prices surge past $93/oz, Ross McElroy and heavyweights like Eric Sprott have set a $5.00 institutional floor on this generational 125M oz domestic resource.
With China shutting export doors and silver officially added to the U.S. Critical Minerals list, the resource war is on. Every EV, solar panel, and 5G tower runs on silver. Discover how Americore Resources Corp. is positioning to secure the essential metal America needs.
In 2022, Philip Morris paid US$16 billion for Swedish Match—not for nicotine, but for the delivery platform. Now a micro-cap is positioning itself earlier on that same continuum. Doseology Sciences Inc. is assembling the infrastructure, leadership, and thesis to build the next generation of oral stimulant formats. Control is becoming the category.
ISSUED ON BEHALF OF ONCOLYTICS BIOTECH Groundbreaking breast and pancreatic cancer data suggest Oncolytics Biotech (NASDAQ: ONCY) (TSX: ONC) is vastly undervalued—but not for long. Every so often, a biotech company achieves clinical milestones that could redefine treatment paradigms, yet the market fails to react immediately. For savvy investors, these moments offer a rare opportunity […]
While HeartFlow commands a multi-billion dollar valuation, Ventripoint Diagnostics is quietly solving the heart’s most difficult challenge with FDA-cleared AI. Backed by clinical validation from Mayo Clinic and Duke, this ‘Device-as-a-Service’ technology is positioned for a potentially strong re-rating. Read the full analysis.
